TY - JOUR
T1 - Management of side effects of novel therapies for multiple myeloma
T2 - Consensus statements developed by the international myeloma foundation's urse leadership board
AU - Bertolotti, Page
AU - Bilotti, Elizabeth
AU - Colson, Kathleen
AU - Curran, Kathleen
AU - Beth, Faiman
AU - Doss, Deborah
AU - Gavino, Maria
AU - Jenkins, Bonnie
AU - Lilleby, Kathy
AU - Love, Ginger
AU - Mangan, Patricia A.
AU - Mccullagh, Emily
AU - Miceli, Teresa
AU - Miller, Kena
AU - Rogers, Kathryn
AU - Rome, Sandra
AU - Sandifer, Stacey
AU - Smith, Lisa C.
AU - Tariman, Joseph D.
AU - Westphal, Jeanne
PY - 2008/6
Y1 - 2008/6
N2 - Nurses play an essential role in managing the care of patients with multiple myeloma, who require education and support to receive and adhere to optimal therapy. The International Myeloma Foundation created a Nurse Leadership Board comprised of oncology nurses from leading cancer centers and community practices. An assessment survey identified the need for specific recommendations for managing key side effects of novel antimyeloma agents. Myelosuppression, thromboembolic events, peripheral neuropathy, steroid toxicities, and gastrointestinal side effects were selected for the first consensus statements. The board developed recommendations for healthcare providers in any medical setting, including grading of side-effect toxicity and strategies for managing the side effects in general, with specific recommendations pertaining to the novel agents.
AB - Nurses play an essential role in managing the care of patients with multiple myeloma, who require education and support to receive and adhere to optimal therapy. The International Myeloma Foundation created a Nurse Leadership Board comprised of oncology nurses from leading cancer centers and community practices. An assessment survey identified the need for specific recommendations for managing key side effects of novel antimyeloma agents. Myelosuppression, thromboembolic events, peripheral neuropathy, steroid toxicities, and gastrointestinal side effects were selected for the first consensus statements. The board developed recommendations for healthcare providers in any medical setting, including grading of side-effect toxicity and strategies for managing the side effects in general, with specific recommendations pertaining to the novel agents.
UR - http://www.scopus.com/inward/record.url?scp=49649085808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49649085808&partnerID=8YFLogxK
U2 - 10.1188/08.CJON.S1.9-12
DO - 10.1188/08.CJON.S1.9-12
M3 - Article
C2 - 18490252
AN - SCOPUS:49649085808
SN - 1092-1095
VL - 12
SP - 9
EP - 12
JO - Clinical journal of oncology nursing
JF - Clinical journal of oncology nursing
IS - SUPPL. 3
ER -